Handling anticancer drugs: From hazard identification to risk management?

Annals of the New York Academy of Sciences

Volumn 1076, Issue , 2006, Pages 628-634

  Sorsa, Marja ^a   Hämeilä, Mervi ^b   Järviluoma, Eija ^c  

^a CA ConsultArt Ltd   (Finland)

^b FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Anticancer drugs; Biomarkers; Biomonitoring; Cytostatics; Exposure assessment

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; ASPARAGINASE; AZATHIOPRINE; BLEOMYCIN; BUSULFAN; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DAUNORUBICIN; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; MITOMYCIN; MITOXANTRONE; PACLITAXEL DERIVATIVE; PODOPHYLLOTOXIN DERIVATIVE; PROCARBAZINE; THIOTEPA; TOPOTECAN; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

BIOLOGICAL MONITORING; CONFERENCE PAPER; ENVIRONMENTAL MONITORING; EXPOSURE; HAZARD ASSESSMENT; HOSPITAL PERSONNEL; HUMAN; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; RISK MANAGEMENT;

EID: 33845655552     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1371.008     Document Type: Conference Paper

References (19)

1. FALCK, K., P. GRÖHN, M. SORSA, et al. 1979. Mutagenicity in urine of nurses handling cytostatic drugs. Lancet i: 1250-1251.
2. SIEBERT, D. & U. SIMON. 1973. Cyclophosphamide. Pilot study of genetically active metabolites in urine of a treated human patient. Mutat. Res. 19: 65-72.
3. SORSA, M., K. HEMMINKI & H. VAINIO. 1985. Occupational exposure to anticancer drugs - potential and real hazards. Mutat. Res. 154: 135-149.
4. SORSA, M. & D. ANDERSON. 1996. Monitoring of occupational exposure to cytostatic anticancer agents. Mutat. Res. 355: 253-261.
5. INTERNATIONAL AGENCY FOR RESEARCH ON CANCER. 2001. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans Vol. 76. Some Antiviral and Antineoplastic Drugs, and Other Pharmaceutical Agents. Lyon, France.
6. DEPARTMENT OF HEALTH AND HUMAN SERVICES (NIOSH). 2004. Occupational hazards in hospitals. Antineoplastic agents. DHHS (NIOSH) Public. 102: 1-13.
7. CONNOR, T.H., R. W. ANDERSON, P.J.M. SESSINK, et al. 1999. Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. Am. J. Health. Syst. Pharm. 56: 1427-1432.
8. ZIEGLER, E., H.J. MASON & P.J. BAXTER. 2002. Occupational exposure to cytotoxic drugs in two UK oncology wards. Occup. Environ. Med. 59: 608-612.
9. HÄMEILÄ, M., K. AALTONEN, T. SANTONEN, et al. 2003. Altistuminen solunsal-paajille apteekki- ja hoitotyössä. Final report. Finnish Institute of Occupational Health, Helsinki, Finland.
10. NYGREN, O., B. GUSTAVSSON, L. STRÖM & A. FRIBERG. 2002. Cisplatin contamination observed on the outside of drug vials. Ann. Occup. Hyg. 46: 555-557.
11. MASON, H.J., J. MORTON, S.J. GARFITT, et al. 2003. Cytotoxic drug contamination on the outside of vials delivered to a hospital pharmacy. Ann. Occup. Hyg. 47: 681-685.
12. SESSINK, P.J.M., M.C.A. VAN DE KERKHOF, R.B.M. ANZION, et al. 1994. Environmental contamination and assessment of exposure to anti-neoplastic agents by determination of cyclophosphamide in urine of exposed pharmacy technicians: is skin absorption an important exposure route? Arch. Env. Health 49: 165-169.
13. TURCI, R., C. SOTTANI, A. RONCHI & C. MINOIA. 2002. Biological monitoring of hospital personnel occupationally exposed to antineoplastic agents. Toxicol. Lett. 134: 57-64.
14. PETHRAN, A., R. SCHIERL, K. HAUFF, et al. 2003. Uptake of antineoplastic agents in pharmacy and hospital personnel. Part I: monitoring of urine concentrations. Int. Arch. Occup. Environ. Health 76: 5-10.
15. PILGER, A., I. KÖHLER, H. STETTNER, et al. 2000. Long-term monitoring of sister chromatid exchanges and micronucleus frequencies in pharmacy personnel occupationally exposed to cytostatic drugs. Int. Arch. Occup. Environ. Health 73: 442-448.
16. MALUF, S.W. & B. ERDTMANN. 2000. Follow-up study of the genetic damage in lymphocytes of pharmacists and nurses handling antineoplastic drugs evaluated by cytokinesis-block micronuclei analysis and single cell gel electrophoresis assay. Mutat. Res. 47: 21-27.
17. ÛNDEGER, Û., N. BASARAN, A. KARS & D. GÜC. 1999. Assessment of DNA damage in nurses handling antineoplastic drugs by the alkaline COMET assay. Mutat. Res. 439: 277-285.
18. BURGAZ, S., B. KARAHALIL, Z. CANH, et al. 2002. Assessment of genotoxic damage in nurses occupationally exposed to antineoplastics by the analysis of chromosomal aberrations. Human Exp. Toxicol. 21: 129-135.
19. DUTCH EXPERT COMMITTEE ON OCCUPATIONAL STANDARDS. 2005. Health-based calculated occupational cancer risk values. Cyclophosphamide. Cisplatin. Gezondheidsraad. 02, 03 OSH.